EMBL Courses and Conferences during the Coronavirus pandemic
With the onsite programme paused, many of our events are now being offered in virtual formats.
Registration is open as usual for many events, with back-up plans in place to move further courses and conferences online as necessary. Registration fees for any events affected by the COVID-19 disruption are fully refundable.
More information for participants of events at EMBL Heidelberg can be found here.
Education, Training and Research in an ever changing geopolitical and innovation ecosystem
Pierre Meulien, Executive Director, Innovative Medicines Initiative
Pierre Meulien is executive director of the Innovative Medicines Initiative (IMI), a 5 billion Euro public-private partnership between the European Union and the European pharmaceutical industry. At IMI, he is responsible for the overall management of the programme, which works to improve and accelerate the drug development process by facilitating collaboration between the key players involved in health research. Previously, Meulien was president and CEO of Genome Canada, where he raised money and oversaw the launch of novel projects and networks in the field of genomics-based technologies. Prior to that, he was chief scientific officer for Genome British Columbia and was the founding CEO of the Dublin Molecular Medicine Center. Meulien also worked with the French biotechnology company Transgene and with Aventis Pasteur (now Sanofi Pasteur). He has a Ph.D. in molecular biology from the University of Edinburgh and carried out a postdoctoral fellowship at the Institut Pasteur in Paris.